Table 2.
Clinical characteristics of patients during the 12 months prior to treatment
| Characteristics | Mepolizumab (n=413) | Omalizumab (n=1834) | P-value |
|---|---|---|---|
|
| |||
| Comorbid conditions, n (%)a | |||
| Allergic rhinitis | 288 (69.7) | 1,412 (77.0) | 0.002 |
| Respiratory infections | 178 (43.1) | 804 (43.8) | 0.784 |
| Sinusitis (acute/chronic) | 146 (35.4) | 483 (26.3) | <0.001 |
| COPD | 123 (29.8) | 403 (22.3) | 0.001 |
| Nasal polyps | 79 (19.1) | 127 (6.9) | <0.001 |
| Hypereosinophilic syndrome | 63 (15.3) | 35 (1.9) | <0.001 |
| Rheumatoid arthritis | 14 (3.4) | 22 (1.2) | 0.001 |
| EGPA | 10 (2.4) | 5 (0.3) | <0.001 |
| Atopic dermatitis | 9 (2.2) | 149 (8.1) | <0.001 |
| Chronic idiopathic urticaria | 2 (0.5) | 388 (21.2) | <0.001 |
| Asthma treatment, n (%)b | |||
| Any corticosteroid | 392 (94.9) | 1,630 (88.9) | <0.001 |
| Oral corticosteroidc | 385 (93.2) | 1,500 (81.8) | <0.001 |
| Inhaled corticosteroid | 180 (43.6) | 476 (26.0) | <0.001 |
| SABA | 337 (81.6) | 1,334 (72.7) | <0.001 |
| LAMA | 132 (32.0) | 296 (16.1) | <0.001 |
| LTRA | 287 (69.5) | 1,269 (69.2) | 0.905 |
| Fixed-dose ICS with LABA | 332 (80.4) | 1,041 (56.8) | <0.001 |
| Triple combination (ICS + LABA + LAMA) | 112 (27.1) | 265 (14.4) | <0.001 |
Notes:
a
Comorbidities with ≥2% prevalence in either group are shown.
b
Asthma treatments show patients with ≥1 prescription claim(s) or administration(s) for the asthma treatment indicated, categories are not mutually exclusive. Of note: patients with a claim or administration for triple combination therapy are also included in the ICS, LABA, LAMA, and fixed-dose ICS with LABA lines.
c
Includes both acute and chronic use.
Abbreviations: EGPA, eosinophilic granulomatosis with polyangiitis; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; LTRA, leukotriene receptor antagonist; SABA, short-acting β2-agonist.